MycRX Pty Ltd is developing novel, small molecule therapeutics for the treatment of lung cancer.
MycRX is a privately-held biotechnology company based in Melbourne. Working with researchers at CSIRO and Peter MacCallum Cancer Centre (PMCC), we have used proprietary assays to develop multiple series of novel drug-like inhibitors of the oncoprotein Myc.
Myc is a transcription factor that drives expression of genes critical for cell growth, differentiation and metabolism and its dysregulation is implicated in >70% of all cancers. Their compounds represent a world-first in potently and selectively directly blocking Myc function.
This project will focus on developing the Myc inhibitors for the treatment of lung cancer, the fifth most common cancer diagnosed in Australia.
Visit MycRX for more details.
BTB Round: First